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REVIEW ARTICLE

CAR-T cell Therapies for B-cell Lymphoid
Malignancies: Identifying Targets Beyond CD19
Yenny M. Vanegas a, Razan Mohty a, Martha E. Gadd a, Yan Luo a, Mahmoud Aljurf b,
Hong Qin a, Mohamed A. Kharfan-Dabaja a,*
a

Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville,
FL, USA
b
Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

Abstract
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived
from a high-speciﬁcity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically
engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T
cells. Target surface molecule selection is crucial for manufacturing CARs. Ideally, a target surface molecule should be
restricted to tumor cells and minimally expressed or absent on normal tissues. Different CD19-targeted CAR-T cell
therapies have been approved for the treatment of B-cell lymphoid malignancies that are refractory to other therapies,
including indolent and aggressive B-cell non-Hodgkin lymphomas (NHL) and B-cell acute lymphoblastic leukemia (BALL). Despite impressive results, many patients with aggressive and refractory B-cell malignancies do not respond to or
relapse after CD19 CAR-T cell therapies. Thus, several additional strategies are currently being evaluated to overcome
these limitations. This review discusses studies on other promising CAR-T cell targets, including CD20, CD22, BAFF-R,
ROR1, CD70, BCR complex, kappa/lambda light chains, multitargeted CAR-T cells, and combinations of CAR-T cell
therapy with different drugs.
Keywords: Chimeric antigen receptor T-cell therapy, CD19, Targets beyond CD19

1. Introduction

T

he 5-year relative survival outcomes for B-cell
malignancies have improved over the past 60
years, although such improvements depend on the
subtype [1]. During that time, the ﬁeld expanded
owing to better targeted therapies and an improved
understanding of the inherent functions of the immune system. This knowledge revolution introduced a wide array of new clinical therapies,
including oncolytic viruses, immune modulators,
monoclonal antibodies (mAbs), immune checkpoint
inhibitors (ICIs), and chimeric antigen receptor Tcell therapy (CAR-T cell).
Chimeric antigen receptors (CARs) are synthetic
engineered receptors with an antigen recognition

domain derived from a high-speciﬁcity monoclonal
antibody that can target surface molecules on tumor
cells [2]. T cells are genetically engineered to express
CARs, thereby harnessing the antigen-recognition
ability of antibodies and effector function of T cells
[3]. The interaction between CAR-T cells and their
targets leads to the formation of immune synapses
that induce contact-dependent cytotoxicity [4].
Target surface molecule selection is a crucial
determinant for the development of CARs. Ideally, a
target surface molecule should be restricted to
tumor cells at sufﬁcient concentrations to induce an
antigen-speciﬁc activation of T cells, minimally
expressed or absent on normal tissues, and
expressed at the stage of the B-cell lifecycle in a
speciﬁc B-cell malignancy [5]. Several surface
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markers have been identiﬁed, including CD19,
CD20, and CD22, among which CD19 has the
broadest surface expression, followed by CD20 and
CD22.

2. CD19
CD19 is a 95 kDa transmembrane glycoprotein
encoded by the cd19 gene located on the short arm
of chromosome 16 [6]. The surface expression of
CD19 is initially observed in the early B-cell progenitor fraction around the same time as immunoglobulin rearrangement occurs [7]. It is highly
regulated and expressed throughout B-cell development and maturation until its expression is lost at
the plasma cell differentiation stage [7]. CD19 is a
co-receptor protein that functions to augment signals by the pre-BCR/BCR (B-cell receptor), and as a
result, it can modulate B-cell fate at multiple stages
of development [7]. It is one of the most reliable
diagnostic surface markers for B-cell malignancies,
and it is ubiquitously expressed on nearly all malignancies of B-cell origin, including 80% of B-cell
precursor acute lymphoblastic leukemia (B-ALL)
and 88% of B-cell lymphomas [8]. These properties
make it a unique surface molecular target for
treating B-cell malignancies. Nonetheless, CD19 is
also expressed on non-malignant B lymphocytes.
Hence, CD19-targeted therapy can result in B-cell
aplasia, which may require immunoglobulin support and antimicrobial prophylaxis [5].
Several studies assessed the use of CD19 CAR-T
cell for the treatment of B-cell malignancies,
including indolent and aggressive B-cell nonHodgkin lymphoma (NHL) and B-ALL.
2.1. CD19-targeted CAR T-cell for the treatment of
indolent and aggressive B-cell NHL
As of mid-2022, four CD19 CAR T-cell products
have been approved for the treatment of indolent
and/or aggressive B-cell NHL: axicabtagene ciloleucel (Axi-cel), tisagenlecleucel (Tisa-cel), brexucabtagene
autoleucel
(Brexu-cel),
and
lisocabtagene maraleucel (Liso-cel). Axi-cel is
currently approved for the treatment of relapsed/
refractory (R/R) large B-cell lymphoma (LBCL),
including diffuse large B-cell lymphoma (DLBCL),
primary mediastinal large B-cell lymphoma
(PMBCL), high-grade B-cell lymphoma, and DLBCL
arising from follicular lymphoma (FL) after two or
more lines of systemic therapy based on the results
of the ZUMA-1 trial; primary refractory or LBCL
relapsing within 12 months of ﬁrst-line therapy
based on the results of the ZUMA-7 trial; and R/R

FL after two or more lines of systemic therapy based
on the results of the ZUMA-5 trial [9e13].
Tisa-cel was approved for the treatment of LBCL
in May 2018 based on the JULIET trial and in May
2022 for the treatment of R/R FL based on results of
the phase 2 ELARA trial [14e16]. In July 2020,
Brexu-cel was approved for the treatment of adult
patients with R/R mantle cell lymphoma (MCL) who
had been previously treated with a Bruton kinase
inhibitor (BTK) based on the ZUMA-2 study [17].
Additionally,
lisocabtagene
maraleucel
was
approved in February 2021 for the treatment of adult
patients with R/R LBCL after two or more lines of
systemic therapy based on the results of the
TRANSCEND NHL001 study [18].
2.2. CD19-targeted CAR T-cell for the treatment of
R/R B-ALL
In 2017, Tisa-cel was approved for the treatment of
pediatric and young adults (up to 25 years of age)
with R/R B-ALL based on the results of the ELIANA
trial [19]. In 2021, Brexu-cel was also approved for
adult patients with R/R B-ALL based on the results
of the ZUMA-3 study [12,20].
Despite impressive results from these breakthrough studies, many patients with aggressive and
refractory lymphomas still do not respond to
aforementioned CD19 CAR-T therapies. This is also
the case for patients with B-ALL [20,21]. These
therapies introduced a unique class-speciﬁc toxicities, including cytokine release syndrome (CRS)
and neurotoxicity. Therefore, understanding the
mechanism(s) or resistance to various therapies and
determining how to manage expected toxicities are
essential for developing new treatment strategies.
The foremost challenges for CAR T-cell therapy
include identifying effective target antigens, determining the impact of the tumor microenvironment,
reconciling the lack of tumor-killing ability, and
improving CAR-T persistence [22]. One strategy for
addressing resistance has been the identiﬁcation of
targets beyond CD19 [5].

3. CD20
CD20 is a 33e37 kDa non-glycosylated phosphoprotein expressed on the surface of mature undifferentiated B- cells [23]. It is encoded by MS4A1
gene located within a cluster on chromosome 11
[24]. Expression of CD20 begins at the pre-B-cell
stage and persists until terminal differentiation into
plasma cells [23]. In B-cell malignancies, the level of
CD20 expression is variable depending on speciﬁc
lymphoma subtypes, with the lowest CD20
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expression observed in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) and the highest expression observed in
patients with DLBCL and hairy cell leukemia (HCL)
[25]. Anti-CD20 mAbs are integral components of
treatment algorithms of several B-cell malignancies,
namely
rituximab,
obinutuzumab,
and
ofatumumab.
In 2011, Till et al. conducted a pilot study with CD20targeted CAR-T in patients with relapsed indolent Bcell and MCL [26]. In total, 4 patients were enrolled: 3
with R/R MCL and 1 with R/R FL. All patients had
received at least two prior lines of therapy, and 2 had a
prior autologous hematopoietic stem cell transplantation (auto-HCT). Two patients remained progression-free for 12 and 24 months. The third patient
had a partial response (PR) and relapsed 12 months
after infusion [26]. In 2014, Wang et al. reported outcomes of CD20-targeted CAR-T in patients with
chemotherapy-refractory advanced DLBCL [27]. In
total, 7 patients were enrolled: 5 had an objective
response that lasted over 6 months. In terms of the
side effect proﬁle, 1 patient died and 2 had grade 4
gastrointestinal (GI) hemorrhage [27]. In 2016, Zhang
et al. conducted an early phase II trial with CD20
CAR-T for patients with R/R NHL [28]. Eleven patients were enrolled, and treatment with prior cytotoxic or biologic therapies had to be administered at
least 4 weeks before enrollment. The overall response
rate (ORR) was 81.8%, with a complete response (CR)
rate of 54.5%, and the median progression free survival (PFS) was 6 months. No grade 4 toxicities were
observed in this study, although one patient was
diagnosed with CRS affecting the lungs [28].
These initial trials evaluated CD20 as a possible
target in CAR T-cell therapy. The main limitation of
using CD20 as a target is the prior use of anti-CD20
immunotherapy in many B-cell malignancies. A
major concern is the downregulation of CD20 after
anti-CD20 therapy, which in principle may limit
CAR-T efﬁcacy. In 2016, Rufener et al. evaluated the
activity of CD20 CAR-T in the presence of various
concentrations of rituximab in vivo and in vitro [29].
The study demonstrated that CAR binding sites on
CD20þ tumor cells were blocked by rituximab in a
dose-dependent manner and showed reduced
cytokine secretion and cytotoxicity. In murine
models, rituximab did not seem to impair CAR-T
activity [29]. The possible effect of other anti-CD20
mAbs on the efﬁcacy of CAR T cells is presently
unknown. Interestingly, CD20 has adopted the role
of a safety switch in CAR development to capitalize
on clearance of the CAR-T with rituximab through
complement-dependent cytotoxicity and antibodydependent cell-mediated cytotoxicity [30].
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Several ongoing trials are assessing CD20 CAR Tcell therapy in R/R NHL (Table 1). Based on previous investigations, CD20 remains an appealing
target antigen for CAR-T therapy. Nonetheless,
sustained responses to therapy continue to be
limited, and the side effect proﬁle remains a signiﬁcant concern.

4. CD22
CD22 is a 140 kDa cell surface glycoprotein
encoded by hcd22 gene located on the long arm of
chromosome 19 at q13.1 [31]. CD22 is a B-lymphocyte-speciﬁc marker that can be seen on pre-B cells.
During maturation, CD22 levels increase, with the
highest levels described in mature B lymphocytes
and a loss of CD22 occurring during terminal differentiation prior to the plasma cell stage [32].
Functional studies in CD22-deﬁcient mice have
demonstrated that it is important in downregulating
BCR mediated signaling, hypothesized to prevent
overstimulation of B cells [33]. It is also involved in
signaling through CD40, a critical receptor in B-cell
activation, proliferation, and class switching [33]. In
a study by Huang et al., up to 70% of the evaluated Bcell lymphoproliferative disorders showed aberrant
expression of CD22 [34]. CD22 has been validated as
a successful target for B-cell leukemias and lymphomas through recombinant immunotoxin and
anti-CD22 therapies [35].
CD22-targeted CAR-T cells have been evaluated
for their antileukemic effect against B-ALL in vitro
and in vivo in murine models [36]. In 2018, Fry et al.
reported the ﬁrst clinical experience using a CD22
CAR as therapy for B-ALL. In this study, treatment
was administered to 21 patients with R/R B-ALL
who had all undergone a prior allogeneic hematopoietic stem cell transplantation (allo-HSCT);
moreover, 71% had received prior CD19-directed
CAR-T [37]. The patients were evaluated at 3-, 6and 9-months post-infusion. Twelve (57%) patients
achieved CR, with three of these patients achieving
lasting remission (21 months). Out of 10 patients
who had previously received CD19-targeted
immunotherapy, 9 achieved a CR, although 8
relapsed within 1.5e12 months following infusion
[37]. Relapse was associated with diminished CD22
surface expression. In terms of the side effect proﬁle, 76% had CRS (any grade), although the majority
were mild, with only 2 patients experiencing grade 3
CRS [37].
In 2019, Pan et al. presented results of CD22 CART in R/R B-ALL [38]. This study included 34 patients,
among which 31 (91%) had failed a prior CD19
CAR-T and 13 (38%) patients had a prior allo-HSCT.
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Table 1. Ongoing CD20-targeted CAR-T cell therapy trials for B-cell malignancies.
Study type

Indication

CAR-T product

Status

Identiﬁer

Center

Phase I/II

R/R NHL, CLL/SLL

CD20 CAR-T cells

Recruiting

NCT03277729

Phase I

R/R
Lymphoma

CD20 CAR-T cells

Recruiting

NCT04169932

Phase I

R/R B-cell lymphoma treated with
prior CD19 CAR-T
therapy
R/R DLBCL treated
with prior CD19
CAR-T therapy
R/R CD20þ B-cell
lymphomas
and
NHL

C-CAR066

Unknown

NCT04036019

C-CAR066

Unknown

NCT04316624

MB-CART20.1

Active, not
recruiting

NCT03664635

Phase I

R/R
B-cell
Lymphomas

CD20 CAR-T cells

Recruiting

NCT03576807

Phase I/II

R/R
CD-20
expressing
B-cell
malignancies after
at least one standard chemotherapy
and one salvage
regimen

CD20 CAR-T cells

Unknown

NCT02710149

Fred
Hutch/University of Washington
Cancer
Consortium
First
Afﬁliated
Hospital
with
Nanjing
Medical
University
Shanghai
Tongji
Hospital,
Tongji
University School
of Medicine
Institute of Hematology & Blood
Diseases Hospital
University Hospital
of Cologne
Universit€atsklikum
Leipzig
Afﬁliated Hospital
of Xuzhou Medical
University
Southwest Hospital
of Third Millitary
Medical University

Phase I

Phase I

B-cell

Abbreviations: R/R e relapsed or refractory NHL - non-Hodgkin lymphoma, B-ALL e B-cell acute lymphoblastic leukemia, DLBCL e
diffuse large B-cell lymphoma, CLL/SLL e Chronic lymphocytic leukemia/small lymphocytic lymphoma.

CD22 expression was measured by ﬂow cytometry,
with 30 of 34 patients having CD22þ blasts and 2
having CD22þ extramedullary disease. Thirty patients survived for 30 days or longer, and the CR rate
was 70.5% at day 30. Only 11 patients were followed
for a longer duration, and they were bridged to alloHSCT. Of the 11 CR patients, 2 died of transplantrelated mortality at 1.5 and 6 months, 1 had a
relapse at 1.1 months, and 8 remained in remission
at 4.6e13.3 months after allo-HSCT. CRS was reported in 31/34 (96%) patients, with only 2 having
grade 3e4 CRS. Grade 2 neurotoxicity was observed
in 1 case. Four patients died: 2 died from severe
infection, 1 died from severe CRS, and 1 died from
veno-occlusive disease [38].
CD22-targeted CAR-T cells are currently being
evaluated for the treatment of other R/R B-cell malignancies (Table 2). Preliminary data from phase I/
Ib clinical trial (NCT04088890) recruiting patients
with R/R LBCL or transformed lymphomas after
CD19-targeted CAR-T cell therapy indicate good
tolerance and CR in their ﬁrst 3 patients after a
mean follow-up of 7.8 months (range, 6e9.3 months)
[39].
Although data are still emerging, similar mechanisms of resistance may occur between CD19-

targeted CAR-T therapy and CD22-targeted CAR Tcell therapy. While the mechanisms(s) remain
poorly understood, downregulation of surface antigens after targeted therapy continues to be an area
of interest. Some studies have suggested that CD22
protein downregulation after CD22 CAR T-cell
therapy may occur at the post-translational level,
with different CD22 splice forms being found [40].
Understanding these mechanisms may help elucidate possible combination therapies with CAR-T to
reduce the rate of relapse and overcome resistance.

5. Other targets
Although the aforementioned targets have potential usefulness, few antigens truly fulﬁll the requirements of an effective target surface molecule
[22]. One of the major challenges is ensuring safety
and limiting “off target” effects. The second major
challenge is decreasing early relapse through antigen escape mechanisms. Currently, many other Bcell targets are being evaluated for the treatment of
B-cell malignancies [41]. To clarify these ﬁndings,
we sorted these targets into different subgroups: a.
targets for B-cell survival and b. targets for B-cell
receptor signaling. B-cell survival targets include B-
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Table 2. Ongoing CD22-targeted CAR-T cell therapy trials for B-cell malignancies.
Study type

Indication

CAR-T product

Status

Identiﬁer

Center

Phase I

R/R B-ALL

CD22 CAR-T cells

Recruiting

NCT04546906

Phase I

R/R B-ALL

CD22 CAR-T cells

Recruiting

NCT03999697

Phase I

R/R B-ALL

CD22 CAR-T cells

Recruiting

NCT03825731

Phase I

R/R B-ALL

CD22 CAR-T cells

Terminated

NCT02588456

Phase I

CD22þ R/R B-ALL
and
B-cell
malignancies

CD22 CAR-T cells

Recruiting

NCT03262298

Phase I

R/R CD22þ pediatric B-ALL or B-cell
lymphoma
Pediatric
and
young adult R/R
CD22þ B-cell ALL
or lymphoma
Pediatric
and
Young Adult CD
22þ leukemia or
lymphoma

CD22 CAR-T cell

Active, not
recruiting

NCT03244306

Hebei
yanda
Ludaopei Hospital
BeiJing
Ludaopei
Hospital
Anhui
Provincial
Hospital
Hebei
Yanda
Ludaopei Hospital
Abramson Cancer
Center of the University
of
Pennsylvania
Afﬁliated Hospital
to Academy of Military
Medical
Sciences
Seattle Children's
Hospital

CD22 CAR-T cells

Enrolling by
invitation

NCT04088864

Stanford University

SCRI-CAR22v2

Recruiting

NCT04571138

Phase II

R/R pediatric
ALL

Recruiting

NCT04340167

Phase I/II

R/R B-ALL, CLL
and NHL
R/R CD22þ B-ALL,
aggressive
B-cell
NHL
R/R B-ALL and R/R
B-cell Lymphomas

Autologous humanized
anti-CD22 chimeric antigen
receptor T-cells
Anti-CD22-CAR-T cells

Children's Hospital
Los Angeles
Children's National
Hospital
Riley Hospital for
Children
Texas
Children's
Hospital
Seattle Children's
Hospital
Beijing
Boren
Hospital

Not yet
recruiting
Recruiting

NCT04163575
NCT04088890

anti-

Recruiting

NCT04007978

CAR-T

Recruiting

NCT02935153

Phase Ib

Phase I/II

Phase I/Ib

Phase I

Phase I/II

B-

CD22 CAR-T cells

Third-generation
CD22 CAR-T cells

R/R CD22þ B-ALL
and
B-cell
lymphomas
R/R
B-cell
malignancies

CD22-targeted
cells
CD22 CAR-T cells

Recruiting

NCT02794961

Phase I

R/R NHL after
CD19 CAR-T cell
therapy

Retroviral
vector-transduced CD22 CAR-T cells

Recruiting

NCT02721407

Phase I

R/R CD22þ B-cell
Malignancies

CD22 CAR-T cells

Recruiting

NCT02315612

Phase I/II

Hebei
Yanda
Ludaopei Hospital
Stanford University

Union
Hospital,
Tongji
Medical
College, Huazhong
University of Science
and
Technology
Southwest Hospital
of Third Millitary
Medical University
Afﬁliated hospital
of Xuzhou medical
college
Xinqiao Hospital of
Chongqing
Xuzhou
Medical
University
National Institutes
of Health Clinical
Center

Abbreviations: R/R e relapsed or refractory; NHL - non-Hodgkin lymphoma; B-ALL e B-cell acute lymphoblastic leukemia, DLBCL e
diffuse large B-cell lymphoma.
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cell activating factor receptor or BAFF-R (B
lymphocyte stimulator, BLyS, CD257, TALL-1, or
TNFRSF13C); ROR1 (receptor tyrosine kinase-like
orphan receptor or neurotrophic tyrosine kinase,
receptor-related 1 (NTRKR1)); and CD70 (tumor
necrosis factor ligand 8A, CD27L). B-cell receptor
signaling candidates include CD79b (Ig-beta, B-cell
antigen receptor complex-associated protein beta
chain) and Immunoglobulin kappa (k) light chain.

in the bone marrow, parathyroid cells, pancreatic
islet cells, adipocytes, and several areas of the GI
tract, albeit at lower levels than in cancer cells [52].
Thus, ROR1-speciﬁc CAR T cells may negatively
impact the B-cell compartment and have signiﬁcant
on-target off-tumor toxicity. Early clinical studies
evaluating ROR-1 CAR-T for treatment of CLL,
MCL, ALL, stage IV non-small cell lung cancer
(NSCLC), or triple-negative breast cancer (TNBC)
(NCT04690595) are underway.

5.1. B-cell survival targets
5.2. CD70-targeted CAR-T cell therapy
5.1.1. BAFF-R-targeted CAR T-cell therapy
BAFF-R is a B-cell marker selectively expressed in
mature B cells. BAFF and its receptor BAFF-R
modulate signaling cascades critical for B-cell
development and survival [42]. Without BAFF-R, a
profound reduction in circulating mature B cells
occurs. Therefore, it is an attractive surface target
since it is more selectively expressed in mature B
cells and present on the surface of several different
B-cell neoplasms, including FL, DLBCL, MCL,
Burkitt lymphoma and CLL [43]. In vitro and xenograft studies using BAFF-R-targeted CAR-T in
CD19-negative B-ALL and lymphoma cell lines
have shown cytotoxicity in vitro and tumor eradication in vivo [44e46]. Other pre-clinical studies have
also evaluated targeting soluble BAFF ligand. BAFF
is a soluble protein that binds to 3 receptors on B
cells: BAFF-R, B-cell maturation antigen (BCMA),
and transmembrane activator and CAML interactor
(TACI) [47]. Wong et al. developed a ligand-based
CAR and generated BAFF CAR-T cells. Their study
demonstrated cytotoxicity of BAFF CAR T cells
against MCL, ALL, and multiple myeloma (MM)
cells in vitro and in vivo in xenograft models [47].
Early clinical studies evaluating BAFFR-CAR-T for
the treatment of R/R B-ALL are currently underway
(NCT04690595).
5.1.2. ROR1-targeted CAR-T cell therapy
ROR1 is a tyrosine kinase that plays a major role
in embryonic and cancer development [48]. ROR1 is
expressed at high levels in MCL and CLL, and results have indicated that higher ROR1 levels occur
with accelerated disease progression and adverse
survival prognosis in CLL [49,50]. Jiang et al. showed
that increased levels of ROR1 expression occurred
in patients with relapsed MCL after CD19 CAR-T
cell therapy and effective therapy with anti-ROR1
antibody VLS-101 [50].
ROR1 targeting CAR T cells displayed promising
anti-tumor effects in pre-clinical studies against
CLL and MCL [51]. However, several other normal
tissues also express ROR1, such as B-cell precursors

CD70 is the membrane ligand of CD27, which
belongs to the tumor necrosis factor (TNF) family
and is essential in regulating lymphocyte growth
and differentiation [53]. Expression of CD70 has
been reported for DLBCL, MCL, FL, Hodgkin's
lymphoma, Waldenstr€
om macroglobulinemia, and
MM, but rarely for normal B cells or T cells [54].
Dysregulation of the CD70:CD27 axis, speciﬁcally
the frequent co-expression of CD70 and CD27 in
malignancy, identiﬁes it as an attractive new target
[55]. In 2021, Deng et al. reported the development of
novel CAR T cells against CD70 and their potential
anti-tumor effect in CD19-positive and CD19-negative murine models [54]. However, CD70 expression
in tumor cells varies amongst tumor types; thus,
dual targeting of CD19 and CD70 represents a
logical future therapeutic strategy.
5.3. B-cell signaling targets
5.3.1. BCR complex associated proteins
BCR is a transmembrane protein complex that
controls B-cell fate and guides cell maturation, survival, anergy, and production of antibodies in
plasma B cells [56]. BCR functions in a complex with
CD79a and CD79b, and the knockdown of any of
these BCR components causes apoptosis in B cells
[56]. BCR-associated proteins are an attractive target
for CAR-T therapy. In fact, their expression is
restricted to the B-cell lineage and is maintained in
most subtypes of NHL, including MCL, DLBCL,
Burkitt's, and FL [57]. CD79a has been investigated
as a prognostic tool in minimal residual disease
(MRD) detection in patients with R/R B-ALL who
received CD19 CAR T-cell therapy as bridging
therapy to allo-HSCT. In this study, 8 patients were
found to be MRD-positive by the presence of
CD79a. The MRD-positive group had worse posttransplant prognosis compared to the MRD-negative group [58]. Currently, no additional pre-clinical
studies have been published describing CD79a
CAR-T cell therapy use.
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However, targeting CD79b has been explored in
patients with R/R NHL and CLL by the
antibodyedrug conjugate polatuzumab [59]. Palanca-Wessels et al. demonstrated an objective
response in 14 of 25 patients, of which 12 had primary refractory DLBCL [59]. In 2019, Ormhøj et al.
developed a novel CAR construct directed against
CD79b and demonstrated antigen recognition and
cytotoxicity in a MCL cell line and patient-derived
xenograft models [57]. There is an ongoing clinical
trial (NCT04609241) evaluating the safety of CD79b
CAR-T cells in patients with R/R ALL and NHL.
5.3.2. Kappa/lambda light chains
Mature B-cell malignancies arise from post-isotype selected cells expressing one type of light
chain. In contrast, non-malignant cells remain
polyclonal. Another method to reduce the risk of Bcell aplasia while targeting B-cell receptors is by
targeting only the light chain isotype expressed by
the clonal malignancy. CAR-T targeting light chains
dates back to 2006 when Vera et al. described kappatargeted CAR T cells against kappa positive tumor
cell lines [60]. This same group showed the results of
phase I clinical trial using kappa-directed CAR T
cells in 16 patients with R/R neoplasias (9 with NHL
and 7 with MM).
Interestingly, they used limited or no lymphodepleting chemotherapy (12.5 mg/kg cyclophosphamide). Clinical responses were reported in 4 of 9
NHL patients: 2 with CR, 1 with PR, and 1 with
stable disease (SD). In terms of the side effect proﬁle, infusion was well tolerated except in 1 patient
with MM who developed grade 3 lymphopenia.
None of the patients had severe CRS [61]. There is a
trial in progress evaluating kappa-targeted CAR-T
in various subtypes of NHL (NCT04223765).
Lambda-targeted CAR-T cells were described by
Ranganathan et al. in 2021 in a pre-clinical setting.
They assessed the efﬁcacy of lambda CAR-T cells in
vitro against patient-derived CLL cells and in vivo
with a patient-derived xenograft model of MCL.
This study reported anti-tumor effects against Ig
lambda positive lymphoma cells in vitro and in vivo
while sparing the reciprocal light chain carrying B
cells [58]. No current clinical trials are evaluating the
safety or efﬁcacy of Ig lambda-directed CAR T cells
in B-cell lymphomas.

6. Multitargeted CAR-T
Although single-target CAR-T methods seeking
the “optimal” target continue to be developed, antigen escape remains one of the major limitations of
these constructs. There are many mechanisms of
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CAR T-cell evasion, including receptor genetic
mutations, cell lineage changes, epitope masking, or
antigen downregulation. As a possible solution, dual
and triple targeting strategies have been developed
to mitigate immune escape. There are several approaches to creating a multitargeted therapy:
generating two or more CAR-T cell populations
targeting different antigens and administering them
concurrently or sequentially; using a bicistronic
vector that encodes two different CARs on the same
cell; and encoding two CARs on the same chimeric
protein (bi-speciﬁc) [62].
In 2013, Hegde et al. observed that targeting HER2
in glioblastoma cell lines would result in the emergence of HER2-null tumor cells [63]. They designed
a mathematical model that predicted that combinational targeting of tumor-associated antigens
could overcome this resistance mechanism. Thus,
they generated bispeciﬁc CARs expressing HER2/
IL-13Ra2, which induced an enhanced effector activity in vitro and in murine models [63]. Interestingly, their model did not predict an added
advantage by targeting a third antigen in the tumor
cohort.
Applying this concept to B-cell malignancies, Zah
et al. designed a bispeciﬁc CAR-T targeting CD19 and
CD20, demonstrated that bispeciﬁc CAR-T was efﬁcacious, and showed that bispeciﬁcity did not affect
CAR-T cell growth, differentiation, exhaustion proﬁle, or lytic capability in vitro [64]. Tong et al. in 2020
reported the results of a phase I/IIa trial using bispeciﬁc CD19/CD20 CAR-T cells in 28 patients with R/
R NHL, including DLBCL, tFL, FL, MCL, CLL/SLL
[65]. All patients were CD20þ, and 79% had CD19þ
tumors by immunohistochemistry (IHC). Most patients had received 3e5 lines of therapy. The ORR
was 79%, with 71% achieving CR and 7% a PR. Out of
4 patients with CD19-disease, 2 achieved CR. In the
intention-to-treat group, the ORR was 67%, with an
estimated 12-month PFS of 59%. In terms of the
adverse events, 100% of patients had adverse events,
with 50% being grade 3 or 4. Also, 50% of the patients
presented with greater than grade 3 neutropenia.
Neurologic events occurred in 6 patients, the majority
being grade 1 or 2 [65].
Zhou et al. in 2020 reported a phase II trial coadministering CD19 and CD20 CAR T cells with a
median of 1.0  10⁶ cells/kg for each type of CAR-T
cell. Twenty-one patients with R/R DLBCL received
CD19 and CD20 CAR-T cell infusion. The ORR was
81%, with 52.4% of the patients achieving a CR.
Median PFS and overall survival (OS) were 5
months and 8.1 months, respectively. CRS occurred
in 100% of patients, with 6% being grade 3e4. Encephalopathy was observed in 23.8% of patients.
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Another possible combination for multitargeted
CAR-T is using CD19/CD22 CAR T cells. In 2018,
Qin et al. hypothesized that simultaneous targeting
of CD19 and CD22 may reduce the likelihood of
antigen loss, and considering that pan-B antigen
expression may be heterogenous from patient to
patient, they concluded that dual targeting would
overcome interpatient variability in antigen
expression. They compared multiple bi-speciﬁc
targeting strategies in xenograft models, including
co-infusion of 2 different CAR T-cell products, cotransduction of 2 viral CAR vectors into a single T
cell, and a single-CAR construct with two different
antigen-binding speciﬁcities (bivalent CAR) to
simultaneously target CD19 and CD22. The latter
showed comparable efﬁcacy for CD19 and/or CD22
CAR-T cells. In 2021, Spiegel et al. completed a phase
I trial using CD19/CD22 bispeciﬁc CAR-T in adults
with R/R B-ALL and LBCL [66]. Thirty-nine patients
were enrolled in the study, with 17 exhibiting B-ALL
and 22 exhibiting LBCL, and 38 received CD19/
CD22 CAR-T. All the patients in the LBCL group
were CAR-T naïve. ORR was 40%, with 33% of patients achieving CR in the LBCL group. At a median
follow-up of 10 months, the median OS and PFS
were 22.5 months and 3.2 months, respectively. In
the B-ALL group, the ORR was 100%, with 82%
achieving CR. The median follow-up was 9.3
months, and the median OS and PFS were 11.8
months and 5.8 months, respectively. In terms of
toxicity, CRS occurred in 76% of patients, of which
5% experienced grade >3 CRS. Neurotoxicity
occurred in 37% of patients, with 4 experiencing
grade >3 neurotoxicity. CD19 þ CD22þ relapse
were associated with resistance to the bispeciﬁc
CAR, which likely reﬂected the intrinsic limitations
of CAR-T cells [66]. Several ongoing trials are evaluating the efﬁcacy of CD19/CD22 CAR-T cells in Bcell malignancies.
Other possible targets have been also explored.
Ruella et al. evaluated the dual targeting of CD19
and CD123 in B-ALL [67]. The argument supporting
the use of CD123 as a CAR-T target antigen was
based on its surface expression in hematopoietic
progenitor cells that exhibited resistance to chemotherapy, its ubiquitous expression, and prior studies
of therapy directed against CD123. In their cohort of
42 patient samples, they found that CD123 was
robustly and homogeneously expressed on the
surface of most ALL blasts. They also noted that a
particular blast subpopulation of CD19 negative but
CD123 positive cells could be responsible for
relapse and resistance to CD19 CAR T cell in B-ALL
patients. Hence, targeting CD19 and CD123 could
prevent CD19- CD123þ relapases. Having shown

that CD123-targeted CAR-T cells were effective
against CD19 negative B-ALL in vitro and in murine
models, they evaluated the efﬁcacy of CD19/CD123
CAR-T cells against CD19þ/CD123þ B-ALL in a
murine model. This combination showed sustained
clearance of the disease [67].
Taking a different approach, trivalent CAR-T cells
have also been developed. Fousek et al. described
CD19/CD20/CD22-targeting CAR-T cells by coexpressing individual CAR molecules on a single T
cell using one tricistronic transgene encoding the
three CAR molecules joined in tandem. These cells
exhibited antigen-speciﬁc anti-tumor activity in
both B-ALL cell lines and murine models, even in
CD19-negative models [68].
The ﬁeld of multitargeted CAR T-cell design is
expanding. Thus, T cells have been created against
speciﬁc targets to limit antigen escape, and other
types of domains are being added to CARs to optimize CAR T-cell efﬁcacy and safety. In addition, as
our understanding of CAR T cells and B-cell malignancies deepens, new strategies may be developed to optimize efﬁcacy of CAR T-cell therapy.

7. Combining CAR-T cells with other drugs
Unfortunately, the duration of remission with the
aforementioned products are short-lived owing to
poor CAR T-cell expansion and limited persistence
[69]. Several hypotheses have been postulated to
understand the causes of relapse, including intrinsic
T-cell defects affecting CAR T-cell manufacturing
and exhaustion [70e72]. T cells derived from patients with CLL exhibit a dysfunctional phenotype
demonstrated by the upregulation of inhibitory receptors, particularly programmed cell death (PD-1),
triggered by the disease itself, the tumor microenvironment, and/or as the result of antineoplastic
treatment(s). This leads to decreased T-cell proliferation and impaired function [73]. It has been hypothesized that CAR T-cell manufacturing is
affected in patients with CLL based on the limited
ability of T cells to expand.
Ibrutinib is an irreversible BTK inhibitor that is
approved for the treatment of CLL. Ibrutinib may
improve T-cell function, enhance anti-tumor effect,
and decrease CAR-T-related adverse effects [71,74].
Based on these observations, the combination of
ibrutinib with CAR T-cell therapy has been studied
to improve CAR T-cell manufacturing and expansion, which may ultimately lead to improved CAR
T-cell function. Pre-clinical data showed that T cells
derived from patients with CLL treated with ibrutinib for 5 or more cycles exhibit an enhanced proliferation capability and signiﬁcantly reduced
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inhibitory receptor expression when cultured in
vitro. These ﬁndings were also seen in vivo in a
murine xenograft MCL model, where a combination
of ibrutinib and CAR T cells led to prolonged tumor
responses [75].
In a phase 2 study, Gill et al. evaluated CD19 CAR
T-cell therapy in patients with CLL that had progressed after at least 6 months of ibrutinib therapy
[76]. Patients continued to receive ibrutinib during
CAR T-cell therapy. A total of 19 patients were
included. CRS was seen in 18 of 19 patients,
although only 2 patients required administration of
tocilizumab. Neurotoxicity was diagnosed in 5 patients. One patient died of severe grade 4 CRS and
ICANS. One death due to infection was observed at
31 months while the patient was still receiving
ibrutinib. Pertaining to efﬁcacy, 7 of 16 evaluable
patients achieved a CR (43.8%) at 3 months. MRD
negativity was seen in 13 of 18 patients at 12 months,
with continued remission at 48 months. PFS at 48
months was 70% [76]. The median OS and PFS were
not reached. Seventeen and eight patients had
detectible and quantiﬁable CAR T cells at 12
months, respectively. Also, at 12 months, 13 of 18
patients had B-cell aplasia, which is a purportedly
proxy marker for persistent CAR T-cell function.
In another pilot study, ibrutinib was started 2
weeks before T-cell collection and continued
through CAR T-cell therapy until at least 3 months
after treatment, and the outcomes were compared to
that of another cohort of CAR T-cell monotherapy
[77]. The ORR values and MRD-negativity rates at
four weeks were 83% and 61%, respectively. The 1year OS was 83% and 1-year PFS were 59% and
38%, with or without ibrutinib therapy (P ¼ .91),
respectively. CRS and neurotoxicity severity
appeared to be lower with the ibrutinib plus CAR Tcell combination relative to CAR T-cell therapy
alone. Of note, one death was reported in each arm
due to cardiac arrhythmia with ibrutinib and CRS
and neurotoxicity without ibrutinib [77]. Overall,
these studies show that the addition of ibrutinib to
CAR T-cell therapy appears safe, is associated with
low incidence of severe CRS, and could lead to
higher and more prolonged responses. The TRANSCEND CLL 004 study is ongoing and includes
different cohorts of CD19 CAR T-cell monotherapy
or other combinatorial approaches using a nonrandomized strategy (NCT03331198).
Another hypothesis to explain the short-term responses after CAR T-cell therapy is CAR T-cell
exhaustion, which was demonstrated by comparing
CAR T-cell antigen expression in responders and
non-responders following CAR T-cell therapy in
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patients with CLL. Reports have shown that in nonresponders, CAR T cells upregulate exhaustion
markers, particularly PD-1, TIM-3, and LAG-3 receptors [78]. Moreover, tumor cells effectively elude
the immune system by the tumor escape mechanism through inhibitory ligands (PD-L1), thus
leading to decreased CAR-T lytic function and
cytokine production and limiting the anti-tumor
efﬁcacy [79].
CPI, including anti-PD1 and anti-PDL1 (ligand for
PD-1), showed promising results in the treatment of
several malignancies [79]. Based on these data, it
has been hypothesized that adding CPI to CAR Tcell therapy could salvage CAR T-cell exhaustion,
enhance the therapeutic function, and potentially
reduce the risk of toxicity [79]. Chong et al. showed
that pembrolizumab therapy in patients with R/R
B-cell lymphoma that progressed after CD19 CAR
T-cell therapy is safe and leads to re-expansion of
CAR T cells, potentially resulting in better clinical
responses [80]. In another phase I dose-escalation
trial, durvalumab, an anti-PD-L1 monoclonal antibody, was combined with CD19 CAR T-cell therapy
(JCAR014) for R/R aggressive B-cell lymphoma [81].
A total of 15 patients were included. Patients
received durvalumab after (21e28 days) or before (1
day) CAR-T infusion for up to 10 cycles until disease progression or toxicity. The ORR was 50%,
with 5 patients achieving CR. Four of six patients
who were initially non-responding achieved
response after 5 cycles of durvalumab. For adverse
events, ﬁve and one patients developed CRS and
neurotoxicity, respectively, with only one grade 4
CRS. In responding patients, CAR T cells were
detectable after a median of ﬁve months after
infusion (range, 1.7e9.1 months) (NCT02706405)
[81]. Further studies evaluated the addition of other
anti-PD-1, e.g., pembrolizumab and nivolumab,
and an anti-PD-L1, e.g., durvalumab, mAbs to
CD19 CAR T cells in ALL and NHL [81e83]. On the
other hand, the combination of tisa-cel and pembrolizumab in the phase Ib PORTIA trial failed to
show an improved efﬁcacy with this combination
[84]. The authors attributed this failure to the fact
that patients included in PORTIA had more refractory and advanced disease compared to the
JULIET study which was a phase 2 trial which
evaluated tisa-cel monotherapy in R/R NHL [84,85].
Indeed, it showed lower frequency (and severity) of
CRS with the combination. Studies with a larger
cohort of patients and longer follow-up times are
awaited to help identify the optimal schedule and
assess the effect of these combinations on CAR T
cells expansion and toxicity.
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8. Discussion and future directions
The development of CD19 CAR T-cell therapy has
thus far revolutionized the treatment of various
subtypes of B-cell lymphomas, B-ALL, and MM. For
LBCL, survival has improved signiﬁcantly, with a
reported ﬁve-year OS of 42.6% [86]. This compares
favorably with SCHOLAR-1, which showed a twoyear OS of less than 20% using non-CAR T-cell
conventional chemoimmunotherapies [1].
Unfortunately, CD19 CAR T-cell therapies are not
universally effective, and a proportion of patients
will experience disease relapse or progress with a
CD-19 negative phenotype or through other escape
mechanisms. To address these challenges, future
CAR T-cell constructs are evaluating other potential
targets alone or in combination as part of a multitargeted approach. This will likely have a beneﬁcial
effect on improving efﬁcacy and reducing the risk of
recurrence, such as preventing a CD19-negative
phenotype relapse after anti-CD19 CAR-T cell
treatment. An ideal target should also have
increased speciﬁcity in order to reduce the possible
off-target effect(s), which is a limitation of
commercially available CD19 CAR T-cell therapies
as normal (or non-malignant) B cells are also eliminated along with the anti-tumor effect of CD19
CAR T cells.
Another approach evaluated to optimize the efﬁcacy of CD19 CAR T cells combines ibrutinib or ICI.
Although the combination of ibrutinib with CD19
CAR T cells against CLL is feasible and may be
applied in patients with MCL, future studies will
likely evaluate the feasibility of this combination in
other B-cell malignancies. This is also the case for
CPI, which has been shown to reverse CAR T-cell
exhaustion. Both combinations potentially enhance
CAR T-cell persistence and decrease toxicity. Larger
phase III trials are deﬁnitely needed to conﬁrm
these ﬁndings and evaluate other combinatorial
approaches.
Finally, the success of future non-CD19 CAR Tcell products, particularly autologous products, is
dependent on overcoming challenges related to
delayed and/or failed manufacturing. Pursuing an
allogeneic strategy might be a solution to increasing
patients' access to these living therapies and hopefully reducing costs.
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